Canada Post Corp Registered Pension Plan Purchases Shares of 2,910 IQVIA Holdings Inc. (NYSE:IQV)

Canada Post Corp Registered Pension Plan acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,910 shares of the medical research company's stock, valued at approximately $572,000.

Several other institutional investors and hedge funds also recently made changes to their positions in IQV. Synergy Asset Management LLC bought a new position in IQVIA during the 4th quarter worth $33,000. Lee Danner & Bass Inc. bought a new stake in IQVIA in the 4th quarter valued at about $44,000. Zions Bancorporation N.A. raised its position in shares of IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after buying an additional 85 shares in the last quarter. Versant Capital Management Inc grew its position in IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after buying an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in shares of IQVIA during the 4th quarter valued at $60,000. Institutional investors and hedge funds own 89.62% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently commented on IQV. UBS Group decreased their price target on IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. Citigroup lowered their price objective on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Robert W. Baird reduced their target price on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, January 21st. Finally, Truist Financial dropped their price objective on IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. Six research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $241.50.

IQVIA Trading Down 3.7 %

Shares of NYSE IQV traded down $5.37 during midday trading on Monday, reaching $138.54. The stock had a trading volume of 323,729 shares, compared to its average volume of 1,404,551. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company's 50 day moving average price is $176.42 and its 200 day moving average price is $196.40. The firm has a market cap of $24.43 billion, a price-to-earnings ratio of 18.47, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.